Jean-François Pariseau M.Sc., MBA, Partner, Health Venture Fund, BDC Venture Capital
Jean-François Pariseau joined BDC Venture Capital in July 2001. He has over 17 years of investment and entrepreneurial experience in the life sciences sector. He has invested and managed more than $200 million in biopharmaceutical and medical device companies in North America. Jean-Francois’ experience includes transactions in private and in public companies, IPOs, M&A and fund investments. Prior to this, he was CEO of a consulting company specializing in regulatory affairs as well as VP, R&D for a pharmaceutical-product distribution company, both of which he founded. Mr. Pariseau holds a Bachelor of Science in Biotechnology from Université de Sherbrooke, a Master of Science in Biomedical Sciences from Université de Montréal, and an MBA from HEC-Montréal. He currently sits on the Board of Directors of AngioChem Inc., Osprey Pharmaceuticals USA, Profound Medical Inc. and BioQuébec.
Damian Lamb, Genesys Capital Partners Co-Founder and Managing Director
Mr. Lamb is co-Founder and Managing Director of Genesys Capital. He brings a unique experience base, blending skills in both the commercial and technical side of biotechnology. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $200 million in venture capital funds, and has been involved in deploying over $90 million in 18 investments. He currently serves on the Board of Affinium Pharmaceuticals Inc.. He has served on the Board of Ionalytics Corporation (recently sold to Thermo Electron Corp.), Millenium Biologix and was Chairman of the Board of DELEX Therapeutics Inc. when it was sold to YM BioSciences. Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.
Steven Plymale, CEO, Profound Medical Inc.
Mr. Plymale has over two decades of senior management experience in the medical device industry and was most recently the Vice President and General Manager of Xltek, a division of Natus Medical Incorporated. Xltek, formerly a public company, was acquired by Natus Medical in November 2007, and designs, manufactures and sells a broad portfolio of diagnostic monitoring devices for Neurology. Prior to this appointment Mr. Plymale served in various senior management roles within several medical device companies (such as ISG Technologies,/Cedara Software, CryoCath Technology, Claron Technology and The Bluehaven Consulting group). Mr. Plymale brings a unique blend of management skills and experience focusing on Operations, Quality & Regulatory Affairs and Strategic Planning.
William E. Curran
Mr. Curran has extensive experience in operations, finance and executive management. He was formerly President and Chief Executive Officer of Philips Electronics North America. He served in diverse functional and senior management positions during his career with Philips, including as Chief Operating Officer of Philips Medical Systems North America. Mr. Curran currently serves on the Board of 3D Systems (NYSE: DDD) and is Chairman of the Audit Committee and a member of the Executive Committee. He was non-executive Chairman and a Director of Resonant Medical before it was sold to Elekta A.B. in 2010 .He has previously served as a director for companies in the medical, electronics, and software industries.
Arun Menawat, President and CEO, Novadaq Technologies Inc.
Arun Menawat has been Novadaq Technologies Inc.’s President and Chief Executive Officer since April 2003. Previously, he held senior management positions at Cedara Software, Tenneco Inc. and Hercules Inc. His educational background includes a Bachelor of Science in Biology, University of District of Columbia, Washington, District of Columbia, and a Ph.D. in Chemical Engineering, from the University of Maryland, College Park, MD, and a Fellowship in Biomedical Engineering from the National Institute of Health, Bethesda, MD. He also earned an Executive MBA from the J.L. Kellogg School of Management, Northwestern University, Evanston, Illinois.